Prescription medicine / off-label wellness

Naltrexone

Prepared by the ezGLP team. Sources last checked September 5, 2026.

Also known as Low-dose naltrexone, LDN

Routes represented in the knowledgebase: Oral / Subcutaneous (SubQ).

Educational overview

Approved for alcohol and opioid use disorders; low-dose use for pain or inflammation is off-label. It blocks opioid analgesia and can precipitate withdrawal.

Category: Prescription medicine / off-label wellness
Routes represented: Oral / Subcutaneous (SubQ)
Storage context: Follow the product or pharmacy label; requirements vary by route and formulation.

Authoritative overview

Published literature

No validated PubMed or DOI link is currently curated for this entry.

Safety evidence

Common or reported: nausea, headache, dizziness, fatigue, insomnia, vomiting, anxiety, sleepiness.

Serious or important: precipitated opioid withdrawal, liver injury, blocked opioid analgesia.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With opioids

Safety flag

Naltrexone can precipitate severe withdrawal, block analgesia, and prompt dangerous attempts to overcome opioid blockade.

Interaction evidence source

With PT-141

Safety flag

Bremelanotide substantially decreases oral naltrexone exposure and can cause treatment failure.

Interaction evidence source

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.